CRBN: A Potential Drug Target for Various Diseases (G51185)

Target Name: CRBN

NCBI ID: G51185

CRBN

CRBN: A Potential Drug Target for Various Diseases

CRBN, short for condensin-regulated RNA binding protein, is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of RNAhomeostasis, which is the balance between the levels of RNA in the cell and the need for it for gene expression. CRBN plays a crucial role in ensuring that the cell has an adequate amount of RNA for efficient gene expression, while also avoiding the accumulation of excess RNA that can interfere with gene function.

Recent studies have identified CRBN as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and inherited disorders. The exact mechanism by which CRBN is targeted by these drugs is not yet fully understood, but it is known that these drugs work by modulating the activity of CRBN.

One of the main mechanisms by which CRBN is targeted by drugs is through its role in the regulation of microRNA (miRNA) levels. miRNA are small non-coding RNAs that play a critical role in post-transcriptional gene regulation by binding to specific mRNAs and regulating their stability. CRBN is known to interact with miRNA-containing complexes, and studies have shown that it can either enhance or inhibit the activity of these complexes.

Drugs that target CRBN have been shown to be effective in a variety of experimental models for cancer, neurodegenerative diseases, and inherited disorders. For example, studies have shown that inhibitors of CRBN can lead to significant reductions in the levels of miRNA, which can in turn lead to the activation of miRNA-containing pathways that promote cell proliferation and survival.

Another mechanism by which CRBN may be targeted by drugs is through its role in the regulation of gene expression. CRBN has been shown to play a role in the regulation of gene expression by binding to specific DNA sequences and modulating the activity of transcription factors. These interactions between CRBN and DNA sequences can lead to changes in gene expression levels, which can be important for the development of diseases.

In addition to its role in gene expression, CRBN is also involved in the regulation of RNA stability. CRBN has been shown to play a role in the stability of microtubules, which are important for the transport of RNA in the cell. This role in RNA stability can be important for the regulation of gene expression and the development of diseases.

Overall, CRBN is a protein that is involved in a wide range of cellular processes that are important for the development and progression of diseases. As such, it is a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and inherited disorders. Further research is needed to fully understand the mechanism by which CRBN is targeted by these drugs, as well as to develop effective therapies that target this protein.

Protein Name: Cereblon

Functions: Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2 or ILF2 (PubMed:33009960). Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8 (PubMed:20223979, PubMed:24328678, PubMed:25043012, PubMed:25108355). Maintains presynaptic glutamate release and consequently cognitive functions, such as memory and learning, by negatively regulating large-conductance calcium-activated potassium (BK) channels in excitatory neurons (PubMed:18414909, PubMed:29530986). Likely to function by regulating the assembly and neuronal surface expression of BK channels via its interaction with KCNT1 (PubMed:18414909). May also be involved in regulating anxiety-like behaviors via a BK channel-independent mechanism (By similarity)

The "CRBN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CRBN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets